The impetus for this proposed shift in policy stems from a stark disparity between current global health guidelines and the biological reality of infant immunity in the modern era. Currently, the World Health Organization (WHO) recommends a two-dose measles vaccine schedule for all children, with the first dose typically administered between 9 and 12 months of age. This timing was historically based on the assumption that maternal antibodies—immunity passed from mother to child during pregnancy—would provide a sufficient shield for the infant during the first several months of life. However, the systematic review led by MCRI indicates that this protective window is closing much earlier than previously thought, particularly in low- and middle-income countries.
Published in the prestigious Journal of Infectious Diseases, the review represents a massive undertaking in pediatric immunology, synthesizing data from 34 separate journal articles. The researchers analyzed health data from 8,000 babies under nine months of age across various low- and middle-income nations. The findings were concerning: while 81 per cent of infants possessed maternal measles antibodies at the time of birth, those levels plummeted with alarming speed. By the time infants reached four months of age, only 30 per cent retained enough maternal antibodies to be considered protected. By seven months, that figure dropped further to a mere 18 per cent.
This data reveals a "protection gap" of several months where the vast majority of infants have lost their innate maternal immunity but have not yet reached the age required for their first scheduled vaccination. With 70 per cent of babies essentially defenseless by four months old, the current WHO recommendation of waiting until 9 to 12 months for the first dose leaves a significant portion of the global infant population at high risk during a period when the measles virus can be most devastating.
Dr. Lien Anh Ha Do, a lead researcher at MCRI, emphasized that the study’s findings provide a compelling case for earlier intervention. According to Dr. Do, when a first dose of the vaccine was administered to infants between four and seven months of age, it produced a positive immune response and proved to be highly effective in preventing the disease. She noted that an early first dose could provide sustained protection throughout infancy by closing the current gaps in immunity. This could be achieved either by moving the initial dose to an earlier age or by introducing a supplemental early dose into the existing two-dose routine. The goal is to ensure that infants do not spend nearly half of their first year of life without any form of protection against one of the world’s most transmissible diseases.
However, the proposal to lower the vaccination age is not without its complexities and potential drawbacks. Professor Kim Mulholland, a senior researcher at MCRI, pointed out that several significant barriers must be addressed before such a policy could be implemented globally. One of the primary concerns is the potential for an earlier first dose to reduce the vaccine’s overall efficacy as the child grows older. In immunology, there is a phenomenon where the presence of even low levels of maternal antibodies can interfere with the body’s long-term immune response to a vaccine, a trade-off that health officials must weigh carefully.
